This publication summarises the results of the PACIFIC trial, a phase III international randomised study comparing durvalumab with placebo in patients with unresectable, stage III NSCLC. Treatment of stage III NSCLC is curative in intent and the survival benefits associated with durvalumab represent the most significant outcome improvement in two decades. The PACIFIC regimen is now considered the standard of care for patients with nonresectable, stage III NSCLC.
A free full-text version of Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer is available here.
This review was commissioned by AstraZeneca.
Please login below to download this issue (PDF)